Recent Quotes

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
FDMT	4D Molecular Therapeutics	25.16	0.00	0%		672.9M

4D Molecular Therapeutics Frequently Asked Questions

How do I buy 4D Molecular Therapeutics (FDMT) stock?

You can purchase shares of 4D Molecular Therapeutics (NASDAQ: FDMT) through any online brokerage.

View our list of the best stock brokerages.

Who are 4D Molecular Therapeutics's (FDMT) competitors?

Other companies in 4D Molecular Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Curis (NASDAQ:CRIS), Chinook Therapeutics (NASDAQ:KDNY), Eagle Pharmaceuticals (NASDAQ:EGRX) and Syndax Pharmaceuticals (NASDAQ:SNDX).

What is the target price for 4D Molecular Therapeutics (FDMT) stock?

The latest price target for 4D Molecular Therapeutics (NASDAQ: FDMT) was reported by B of A Securities on January 5, 2021. The analyst firm set a price target for 47.00 expecting FDMT to rise to within 12 months (a possible 86.80% upside). 2 analyst firms have reported ratings in the last year.

Current Stock Price for 4D Molecular Therapeutics (FDMT)?

The stock price for 4D Molecular Therapeutics (NASDAQ: FDMT) is $25.16 last updated Today at 8:00:02 PM.

Does 4D Molecular Therapeutics (FDMT) pay a dividend?

There are no upcoming dividends for 4D Molecular Therapeutics.

When is 4D Molecular Therapeutics (NASDAQ:FDMT) reporting earnings?

4D Molecular Therapeutics does not have any upcoming earnings scheduled.

Is 4D Molecular Therapeutics (FDMT) going to split?

There is no upcoming split for 4D Molecular Therapeutics.

What sector and industry does 4D Molecular Therapeutics (FDMT) operate in?

4D Molecular Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.